Editor's note: Recently, Professor Shi Ming's team of Sun Yat-sen University Tumor Prevention and Treatment Center published an article titled "Lanvatinib, teriplizumab combined with hepatic arterial perfusion chemotherapy treatment for advanced stage high-risk liver cancer : A Phase II clinical study of biomolecular exploration" in the authoritative oncology journal "European Journal of Cancer".
study found that the "triple-treatment" regimen of hepatic arterial perfusion chemotherapy combined with lenvatinib and terreprizumab (PD-1) can significantly improve the prognosis of patients. This is the first prospective research result published internationally on the treatment of patients with advanced liver cancer in the "triple-linked plan".
At present, systematic treatment led by atelizumab combined with bevacizumab is the standard treatment plan for patients with advanced liver cancer. However, for patients with high tumor burden, especially high risk of liver cancer, the effect of systemic treatment is not satisfactory.
In order to improve the prognosis of patients with high-risk liver cancer, local treatment combined with systemic treatment regimens are highly recommended in Asia. Previous studies by Professor Shi Ming’s team have shown that hepatic arterial perfusion chemotherapy is effective in unresectable large liver cancer and advanced liver cancer; at the same time, compared with single-agent treatment of lenvatinib, the "triple combination regimen" can significantly improve the progression-free survival and tumor response rate of patients with advanced liver cancer, and the toxic side effects can be tolerated. Therefore, for patients with advanced high-risk liver cancer, Professor Shi Ming's team conducted a phase II study on the effectiveness and safety of the "triple-treatment" plan of hepatic arterial perfusion chemotherapy combined with lenvatinib and terreprizumab, and also explored prognostic markers for patients receiving this plan.
study included 36 subjects from the Sun Yat-sen University Tumor Prevention and Treatment Center, all subjects received a 21-day "triple-choice" treatment. After 8.2 months of median treatment duration, the median progression-free survival of 36 subjects was 10.4 months, and the median survival time was not reached in the preset final analysis. After extended follow-up, the median survival was 17.9 months, the tumor response rate was 63.9%, and the tumor control rate was 88.9%, and the toxic side effects were tolerated. Among them, the lesions in 8 subjects became resectable lesions after treatment. At the same time, we analyzed and determined the peripheral blood of subjects and screened out that the peripheral blood levels of cellular chemokine-28 and cytomodulin can be used as potential prognostic factors for "triple therapy".
Extended follow-up survival curve
The reduction ratio of tumors after treatment
Before treatment (left) and after treatment (right)
In recent years, many medical centers have begun to promote local treatment combined with systemic drug treatment for advanced liver cancer in clinical practice. Many retrospective research results have been published, but there has been a lack of high-level evidence of prospective research results. The results of this study fill the gap in this field and are of great significance to the promotion and application of this joint program in advanced liver cancer.
Copyright Statement
Copyright of this article belongs to Yiyuehui. Welcome to forward and share. If any other media needs to reprint or quote all copyrighted content on this website, they must obtain authorization and indicate "Reprinted from: Yiyuehui" in a conspicuous location.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-